Page last updated: 2024-12-08

8-(di-n-propylamino)-6,7,8,9-tetrahydro-3h-benz(e)indole-1-carbaldehyde

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

8-(di-n-propylamino)-6,7,8,9-tetrahydro-3H-benz(e)indole-1-carbaldehyde: RN refers to (+-)-isomer; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID178081
CHEMBL ID304426
SCHEMBL ID8312369
MeSH IDM0219582

Synonyms (16)

Synonym
8-dipropylamino-6,7,8,9-tetrahydro-3h-benzo[e]indole-1-carbaldehyde
bdbm50035320
(+/-)-8-dipropylamino-6,7,8,9-tetrahydro-3h-benzo[e]indole-1-carbaldehyde
CHEMBL304426 ,
L005583
8-(dipropylamino)-6,7,8,9-tetrahydro-3h-benzo[e]indole-1-carbaldehyde
3h-benz(e)indole-1-carboxaldehyde, 8-(dipropylamino)-6,7,8,9-tetrahydro-
163562-15-0
osu 191
136906-08-6
(+-)-8-(dipropylamino)-6,7,8,9-tetrahydro-3h-benz(e)indole-1-carboxaldehyde
8-(di-n-propylamino)-6,7,8,9-tetrahydro-3h-benz(e)indole-1-carbaldehyde
3h-benz(e)indole-1-carboxaldehyde, 8-(dipropylamino)-6,7,8,9-tetrahydro-, (+-)-
8-dbic
SCHEMBL8312369
DTXSID10929576

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
" Compounds 6 and 8 were found to have high oral bioavailability in the rat (63% and 54%, respectively)."( 6,7,8,9-Tetrahydro-N,N-di-n-propyl-3H-benzindol-8-amines. Derivatives as potent and orally active serotonin 5-HT1A receptor agonists.
Andersson, B; Carlsson, A; Ekman, A; Elebring, T; Lagerkvist, S; Nilsson, J; Stjernlöf, P; Svensson, K; Wikström, H, 1994
)
0.29
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (6)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
5-hydroxytryptamine receptor 1AHomo sapiens (human)IC50 (µMol)0.00120.00010.666410.0000AID1855055
5-hydroxytryptamine receptor 1AHomo sapiens (human)Ki0.00120.00010.532610.0000AID1854986
D(3) dopamine receptorRattus norvegicus (Norway rat)Ki0.07000.00010.25675.8000AID65618; AID65755
5-hydroxytryptamine receptor 1ARattus norvegicus (Norway rat)Ki0.00060.00010.739610.0000AID4102; AID4104; AID4367; AID4368; AID4370
5-hydroxytryptamine receptor 1DHomo sapiens (human)Ki0.17300.00010.808710.0000AID4898
5-hydroxytryptamine receptor 1BHomo sapiens (human)Ki0.36400.00010.54859.2100AID4933
D(2) dopamine receptorRattus norvegicus (Norway rat)Ki0.07200.00000.437510.0000AID65722; AID65724; AID65725; AID65911; AID65913
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (38)

Processvia Protein(s)Taxonomy
behavioral fear response5-hydroxytryptamine receptor 1AHomo sapiens (human)
G protein-coupled receptor signaling pathway5-hydroxytryptamine receptor 1AHomo sapiens (human)
adenylate cyclase-inhibiting serotonin receptor signaling pathway5-hydroxytryptamine receptor 1AHomo sapiens (human)
serotonin receptor signaling pathway5-hydroxytryptamine receptor 1AHomo sapiens (human)
gamma-aminobutyric acid signaling pathway5-hydroxytryptamine receptor 1AHomo sapiens (human)
positive regulation of cell population proliferation5-hydroxytryptamine receptor 1AHomo sapiens (human)
regulation of serotonin secretion5-hydroxytryptamine receptor 1AHomo sapiens (human)
regulation of vasoconstriction5-hydroxytryptamine receptor 1AHomo sapiens (human)
exploration behavior5-hydroxytryptamine receptor 1AHomo sapiens (human)
regulation of dopamine metabolic process5-hydroxytryptamine receptor 1AHomo sapiens (human)
serotonin metabolic process5-hydroxytryptamine receptor 1AHomo sapiens (human)
regulation of hormone secretion5-hydroxytryptamine receptor 1AHomo sapiens (human)
regulation of behavior5-hydroxytryptamine receptor 1AHomo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 1AHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger5-hydroxytryptamine receptor 1AHomo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway5-hydroxytryptamine receptor 1DHomo sapiens (human)
intestine smooth muscle contraction5-hydroxytryptamine receptor 1DHomo sapiens (human)
regulation of locomotion5-hydroxytryptamine receptor 1DHomo sapiens (human)
vasoconstriction5-hydroxytryptamine receptor 1DHomo sapiens (human)
regulation of behavior5-hydroxytryptamine receptor 1DHomo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 1DHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger5-hydroxytryptamine receptor 1DHomo sapiens (human)
adenylate cyclase-inhibiting serotonin receptor signaling pathway5-hydroxytryptamine receptor 1DHomo sapiens (human)
G protein-coupled receptor internalization5-hydroxytryptamine receptor 1BHomo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway5-hydroxytryptamine receptor 1BHomo sapiens (human)
adenylate cyclase-inhibiting serotonin receptor signaling pathway5-hydroxytryptamine receptor 1BHomo sapiens (human)
protein kinase C-activating G protein-coupled receptor signaling pathway5-hydroxytryptamine receptor 1BHomo sapiens (human)
negative regulation of gamma-aminobutyric acid secretion5-hydroxytryptamine receptor 1BHomo sapiens (human)
regulation of dopamine secretion5-hydroxytryptamine receptor 1BHomo sapiens (human)
negative regulation of serotonin secretion5-hydroxytryptamine receptor 1BHomo sapiens (human)
negative regulation of synaptic transmission, GABAergic5-hydroxytryptamine receptor 1BHomo sapiens (human)
response to cocaine5-hydroxytryptamine receptor 1BHomo sapiens (human)
vasoconstriction5-hydroxytryptamine receptor 1BHomo sapiens (human)
drinking behavior5-hydroxytryptamine receptor 1BHomo sapiens (human)
response to ethanol5-hydroxytryptamine receptor 1BHomo sapiens (human)
bone remodeling5-hydroxytryptamine receptor 1BHomo sapiens (human)
regulation of behavior5-hydroxytryptamine receptor 1BHomo sapiens (human)
response to mineralocorticoid5-hydroxytryptamine receptor 1BHomo sapiens (human)
negative regulation of synaptic transmission, glutamatergic5-hydroxytryptamine receptor 1BHomo sapiens (human)
cellular response to alkaloid5-hydroxytryptamine receptor 1BHomo sapiens (human)
cellular response to xenobiotic stimulus5-hydroxytryptamine receptor 1BHomo sapiens (human)
cellular response to temperature stimulus5-hydroxytryptamine receptor 1BHomo sapiens (human)
presynaptic modulation of chemical synaptic transmission5-hydroxytryptamine receptor 1BHomo sapiens (human)
regulation of presynaptic cytosolic calcium ion concentration5-hydroxytryptamine receptor 1BHomo sapiens (human)
positive regulation of vascular associated smooth muscle cell proliferation5-hydroxytryptamine receptor 1BHomo sapiens (human)
regulation of synaptic vesicle exocytosis5-hydroxytryptamine receptor 1BHomo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 1BHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger5-hydroxytryptamine receptor 1BHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (6)

Processvia Protein(s)Taxonomy
G protein-coupled serotonin receptor activity5-hydroxytryptamine receptor 1AHomo sapiens (human)
protein binding5-hydroxytryptamine receptor 1AHomo sapiens (human)
receptor-receptor interaction5-hydroxytryptamine receptor 1AHomo sapiens (human)
neurotransmitter receptor activity5-hydroxytryptamine receptor 1AHomo sapiens (human)
serotonin binding5-hydroxytryptamine receptor 1AHomo sapiens (human)
G protein-coupled serotonin receptor activity5-hydroxytryptamine receptor 1DHomo sapiens (human)
neurotransmitter receptor activity5-hydroxytryptamine receptor 1DHomo sapiens (human)
G protein-coupled serotonin receptor activity5-hydroxytryptamine receptor 1BHomo sapiens (human)
protein binding5-hydroxytryptamine receptor 1BHomo sapiens (human)
serotonin binding5-hydroxytryptamine receptor 1BHomo sapiens (human)
voltage-gated calcium channel activity involved in regulation of presynaptic cytosolic calcium levels5-hydroxytryptamine receptor 1BHomo sapiens (human)
neurotransmitter receptor activity5-hydroxytryptamine receptor 1BHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (8)

Processvia Protein(s)Taxonomy
plasma membrane5-hydroxytryptamine receptor 1AHomo sapiens (human)
synapse5-hydroxytryptamine receptor 1AHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 1AHomo sapiens (human)
dendrite5-hydroxytryptamine receptor 1AHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 1DHomo sapiens (human)
synapse5-hydroxytryptamine receptor 1DHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 1DHomo sapiens (human)
dendrite5-hydroxytryptamine receptor 1DHomo sapiens (human)
endoplasmic reticulum5-hydroxytryptamine receptor 1BHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 1BHomo sapiens (human)
presynaptic membrane5-hydroxytryptamine receptor 1BHomo sapiens (human)
calyx of Held5-hydroxytryptamine receptor 1BHomo sapiens (human)
serotonergic synapse5-hydroxytryptamine receptor 1BHomo sapiens (human)
G protein-coupled serotonin receptor complex5-hydroxytryptamine receptor 1BHomo sapiens (human)
dendrite5-hydroxytryptamine receptor 1BHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 1BHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (43)

Assay IDTitleYearJournalArticle
AID197513Log concentration to inhibit 5-HTP accumulation was determined in rat brain hemispheres1994Journal of medicinal chemistry, Sep-30, Volume: 37, Issue:20
6,7,8,9-Tetrahydro-N,N-di-n-propyl-3H-benzindol-8-amines. Derivatives as potent and orally active serotonin 5-HT1A receptor agonists.
AID4898Binding affinity against 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells, using [3H]-5-HT as the radioligand.1995Journal of medicinal chemistry, Jun-09, Volume: 38, Issue:12
Structure-activity relationships in the 8-amino-6,7,8,9-tetrahydro-3H-benz[e]indole ring system. 1. Effects of substituents in the aromatic system on serotonin and dopamine receptor subtypes.
AID4933Binding affinity against 5-hydroxytryptamine 1D receptor beta expressed in CHO-K1 cells, using [3H]5-HT as the radioligand.1995Journal of medicinal chemistry, Jun-09, Volume: 38, Issue:12
Structure-activity relationships in the 8-amino-6,7,8,9-tetrahydro-3H-benz[e]indole ring system. 1. Effects of substituents in the aromatic system on serotonin and dopamine receptor subtypes.
AID181111compound was tested in vivo for DOPA accumulation in corpus striatum against reserpine-pretreated rats1995Journal of medicinal chemistry, Jun-09, Volume: 38, Issue:12
Structure-activity relationships in the 8-amino-6,7,8,9-tetrahydro-3H-benz[e]indole ring system. 1. Effects of substituents in the aromatic system on serotonin and dopamine receptor subtypes.
AID172487Compound was tested for 5-HT behavioral response in reserpine pretreated rats; +5HT syndrome1993Journal of medicinal chemistry, Jul-23, Volume: 36, Issue:15
(S)- and (R)-8-(di-n-propylamino)-6,7,8,9-tetrahydro-3H-benz[e]indole-1- carbaldehyde: a new class of orally active 5-HT1A-receptor agonists.
AID65911Displacement of the radioligand [3H]spiperone from D2 receptor1994Journal of medicinal chemistry, Sep-30, Volume: 37, Issue:20
6,7,8,9-Tetrahydro-N,N-di-n-propyl-3H-benzindol-8-amines. Derivatives as potent and orally active serotonin 5-HT1A receptor agonists.
AID65722In vitro binding affinity against cloned mammalian Dopamine receptor D2 expressed in CHO cells using [3H]U-86170 as radioligand1995Journal of medicinal chemistry, Jun-09, Volume: 38, Issue:12
Structure-activity relationships in the 8-amino-6,7,8,9-tetrahydro-3H-benz[e]indole ring system. 2. Effects of 8-amino nitrogen substitution on serotonin receptor binding and pharmacology.
AID197517Log concentration to inhibit DOPA accumulation was determined in rat brain striatum1994Journal of medicinal chemistry, Sep-30, Volume: 37, Issue:20
6,7,8,9-Tetrahydro-N,N-di-n-propyl-3H-benzindol-8-amines. Derivatives as potent and orally active serotonin 5-HT1A receptor agonists.
AID4909In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor alpha expressed in CHO cells, by using [3H]5-HT as radioligand1995Journal of medicinal chemistry, Jun-09, Volume: 38, Issue:12
Structure-activity relationships in the 8-amino-6,7,8,9-tetrahydro-3H-benz[e]indole ring system. 2. Effects of 8-amino nitrogen substitution on serotonin receptor binding and pharmacology.
AID177335In vivo evaluation for DOPA accumulation in the limbic system in male rats (sc)1993Journal of medicinal chemistry, Jul-23, Volume: 36, Issue:15
(S)- and (R)-8-(di-n-propylamino)-6,7,8,9-tetrahydro-3H-benz[e]indole-1- carbaldehyde: a new class of orally active 5-HT1A-receptor agonists.
AID177323In vivo evaluation for DOPA accumulation in the corpus striatum in male rats (sc)1993Journal of medicinal chemistry, Jul-23, Volume: 36, Issue:15
(S)- and (R)-8-(di-n-propylamino)-6,7,8,9-tetrahydro-3H-benz[e]indole-1- carbaldehyde: a new class of orally active 5-HT1A-receptor agonists.
AID4935In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor beta expressed in CHO cells, by using [3H]5-HT as radioligand1995Journal of medicinal chemistry, Jun-09, Volume: 38, Issue:12
Structure-activity relationships in the 8-amino-6,7,8,9-tetrahydro-3H-benz[e]indole ring system. 2. Effects of 8-amino nitrogen substitution on serotonin receptor binding and pharmacology.
AID180739The concentration yielding a half maximal decrease of the DOPA was determined in rat brain striatum1994Journal of medicinal chemistry, Sep-30, Volume: 37, Issue:20
6,7,8,9-Tetrahydro-N,N-di-n-propyl-3H-benzindol-8-amines. Derivatives as potent and orally active serotonin 5-HT1A receptor agonists.
AID65724In vitro binding affinity against dopamine receptor D2 using [3H]-Raclopride as radioligand in CHO cells (sc)1993Journal of medicinal chemistry, Jul-23, Volume: 36, Issue:15
(S)- and (R)-8-(di-n-propylamino)-6,7,8,9-tetrahydro-3H-benz[e]indole-1- carbaldehyde: a new class of orally active 5-HT1A-receptor agonists.
AID4367In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1A receptor expressed in CHO cells, by using [3H]8-OH-DPAT as radioligand.1995Journal of medicinal chemistry, Jun-09, Volume: 38, Issue:12
Structure-activity relationships in the 8-amino-6,7,8,9-tetrahydro-3H-benz[e]indole ring system. 2. Effects of 8-amino nitrogen substitution on serotonin receptor binding and pharmacology.
AID180749The concentration yielding a half maximal decrease of the DOPA was determined in rat limbic system1994Journal of medicinal chemistry, Sep-30, Volume: 37, Issue:20
6,7,8,9-Tetrahydro-N,N-di-n-propyl-3H-benzindol-8-amines. Derivatives as potent and orally active serotonin 5-HT1A receptor agonists.
AID197514Log concentration to inhibit 5-HTP accumulation was determined in rat brain striatum1994Journal of medicinal chemistry, Sep-30, Volume: 37, Issue:20
6,7,8,9-Tetrahydro-N,N-di-n-propyl-3H-benzindol-8-amines. Derivatives as potent and orally active serotonin 5-HT1A receptor agonists.
AID1854986Binding affinity to 5-HT1A receptor (unknown origin) assessed as inhibition constant2022Journal of medicinal chemistry, 08-25, Volume: 65, Issue:16
Positron Emission Tomography (PET) Imaging Tracers for Serotonin Receptors.
AID181091compound was tested in vivo for 5-HTP accumulation in corpus striatum against reserpine-pretreated rats, activity expressed as ED501995Journal of medicinal chemistry, Jun-09, Volume: 38, Issue:12
Structure-activity relationships in the 8-amino-6,7,8,9-tetrahydro-3H-benz[e]indole ring system. 1. Effects of substituents in the aromatic system on serotonin and dopamine receptor subtypes.
AID4368Displacement of the radioligand [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor1994Journal of medicinal chemistry, Sep-30, Volume: 37, Issue:20
6,7,8,9-Tetrahydro-N,N-di-n-propyl-3H-benzindol-8-amines. Derivatives as potent and orally active serotonin 5-HT1A receptor agonists.
AID65725Displacement of [3H]spiperone from dopamine receptor D21993Journal of medicinal chemistry, Jul-23, Volume: 36, Issue:15
(S)- and (R)-8-(di-n-propylamino)-6,7,8,9-tetrahydro-3H-benz[e]indole-1- carbaldehyde: a new class of orally active 5-HT1A-receptor agonists.
AID177331In vivo evaluation for DOPA accumulation in the hemispheres in male rats at highest test dose of 12.5 uM/Kg (sc); inactive1993Journal of medicinal chemistry, Jul-23, Volume: 36, Issue:15
(S)- and (R)-8-(di-n-propylamino)-6,7,8,9-tetrahydro-3H-benz[e]indole-1- carbaldehyde: a new class of orally active 5-HT1A-receptor agonists.
AID177315In vivo evaluation for 5-HTP accumulation in the corpus striatum in male rats (sc)1993Journal of medicinal chemistry, Jul-23, Volume: 36, Issue:15
(S)- and (R)-8-(di-n-propylamino)-6,7,8,9-tetrahydro-3H-benz[e]indole-1- carbaldehyde: a new class of orally active 5-HT1A-receptor agonists.
AID4104In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT1993Journal of medicinal chemistry, Jul-23, Volume: 36, Issue:15
(S)- and (R)-8-(di-n-propylamino)-6,7,8,9-tetrahydro-3H-benz[e]indole-1- carbaldehyde: a new class of orally active 5-HT1A-receptor agonists.
AID181097compound was tested in vivo for 5-HTP accumulation in hemispheres (cortex) against reserpine-pretreated rats1995Journal of medicinal chemistry, Jun-09, Volume: 38, Issue:12
Structure-activity relationships in the 8-amino-6,7,8,9-tetrahydro-3H-benz[e]indole ring system. 1. Effects of substituents in the aromatic system on serotonin and dopamine receptor subtypes.
AID4370Binding affinity against 5-hydroxytryptamine 1A receptor from CHO-K1 cells, using [3H]8-OH-DPAT as the radioligand.1995Journal of medicinal chemistry, Jun-09, Volume: 38, Issue:12
Structure-activity relationships in the 8-amino-6,7,8,9-tetrahydro-3H-benz[e]indole ring system. 1. Effects of substituents in the aromatic system on serotonin and dopamine receptor subtypes.
AID180735The concentration yielding a half maximal decrease of the DOPA was determined in rat brain hemispheres; inactive at 12.5 umol/kg1994Journal of medicinal chemistry, Sep-30, Volume: 37, Issue:20
6,7,8,9-Tetrahydro-N,N-di-n-propyl-3H-benzindol-8-amines. Derivatives as potent and orally active serotonin 5-HT1A receptor agonists.
AID181105compound was tested in vivo for 5-HTP accumulation in limbic system against reserpine-pretreated rats,1995Journal of medicinal chemistry, Jun-09, Volume: 38, Issue:12
Structure-activity relationships in the 8-amino-6,7,8,9-tetrahydro-3H-benz[e]indole ring system. 1. Effects of substituents in the aromatic system on serotonin and dopamine receptor subtypes.
AID65755In vitro binding affinity against cloned mammalian Dopamine receptor D3 expressed in CHO cells by, using [3H]-spiperone as radioligand1995Journal of medicinal chemistry, Jun-09, Volume: 38, Issue:12
Structure-activity relationships in the 8-amino-6,7,8,9-tetrahydro-3H-benz[e]indole ring system. 2. Effects of 8-amino nitrogen substitution on serotonin receptor binding and pharmacology.
AID180540The compound was tested in vivo for DOPA accumulation in limbic system against reserpine-pretreated rats1995Journal of medicinal chemistry, Jun-09, Volume: 38, Issue:12
Structure-activity relationships in the 8-amino-6,7,8,9-tetrahydro-3H-benz[e]indole ring system. 1. Effects of substituents in the aromatic system on serotonin and dopamine receptor subtypes.
AID180720The concentration yielding a half maximal decrease of the 5-HTP was determined in rat brain striatum1994Journal of medicinal chemistry, Sep-30, Volume: 37, Issue:20
6,7,8,9-Tetrahydro-N,N-di-n-propyl-3H-benzindol-8-amines. Derivatives as potent and orally active serotonin 5-HT1A receptor agonists.
AID65618Binding affinity against Dopamine receptor D3 from CHO-K1 cells, using [3H]spiperone as the radioligand.1995Journal of medicinal chemistry, Jun-09, Volume: 38, Issue:12
Structure-activity relationships in the 8-amino-6,7,8,9-tetrahydro-3H-benz[e]indole ring system. 1. Effects of substituents in the aromatic system on serotonin and dopamine receptor subtypes.
AID177321In vivo evaluation for 5-HTP accumulation in the limbic system in male rats (sc)1993Journal of medicinal chemistry, Jul-23, Volume: 36, Issue:15
(S)- and (R)-8-(di-n-propylamino)-6,7,8,9-tetrahydro-3H-benz[e]indole-1- carbaldehyde: a new class of orally active 5-HT1A-receptor agonists.
AID1855055Inhibition of 5-HT1A receptor (unknown origin)2022Journal of medicinal chemistry, 08-25, Volume: 65, Issue:16
Positron Emission Tomography (PET) Imaging Tracers for Serotonin Receptors.
AID180724The concentration yielding a half maximal decrease of the 5-HTP was determined in rat limbic system1994Journal of medicinal chemistry, Sep-30, Volume: 37, Issue:20
6,7,8,9-Tetrahydro-N,N-di-n-propyl-3H-benzindol-8-amines. Derivatives as potent and orally active serotonin 5-HT1A receptor agonists.
AID65913Binding affinity against Dopamine receptor D2 from CHO-K1 cells, using [3H]U-86,170 as the radioligand.1995Journal of medicinal chemistry, Jun-09, Volume: 38, Issue:12
Structure-activity relationships in the 8-amino-6,7,8,9-tetrahydro-3H-benz[e]indole ring system. 1. Effects of substituents in the aromatic system on serotonin and dopamine receptor subtypes.
AID197515Log concentration to inhibit 5-HTP accumulation was determined in rat limbic system1994Journal of medicinal chemistry, Sep-30, Volume: 37, Issue:20
6,7,8,9-Tetrahydro-N,N-di-n-propyl-3H-benzindol-8-amines. Derivatives as potent and orally active serotonin 5-HT1A receptor agonists.
AID177319In vivo evaluation for 5-HTP accumulation in the hemispheres in male rats (sc)1993Journal of medicinal chemistry, Jul-23, Volume: 36, Issue:15
(S)- and (R)-8-(di-n-propylamino)-6,7,8,9-tetrahydro-3H-benz[e]indole-1- carbaldehyde: a new class of orally active 5-HT1A-receptor agonists.
AID180715The concentration yielding a half maximal decrease of the 5-HTP was determined in rat brain hemispheres1994Journal of medicinal chemistry, Sep-30, Volume: 37, Issue:20
6,7,8,9-Tetrahydro-N,N-di-n-propyl-3H-benzindol-8-amines. Derivatives as potent and orally active serotonin 5-HT1A receptor agonists.
AID4102In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand in CHO cells (sc)1993Journal of medicinal chemistry, Jul-23, Volume: 36, Issue:15
(S)- and (R)-8-(di-n-propylamino)-6,7,8,9-tetrahydro-3H-benz[e]indole-1- carbaldehyde: a new class of orally active 5-HT1A-receptor agonists.
AID224035Motor activity was measured by motility testing on injecting the compound subcutaneously into rats at the dose of 12.5 umol/kg1994Journal of medicinal chemistry, Sep-30, Volume: 37, Issue:20
6,7,8,9-Tetrahydro-N,N-di-n-propyl-3H-benzindol-8-amines. Derivatives as potent and orally active serotonin 5-HT1A receptor agonists.
AID197518Log concentration to inhibit DOPA accumulation was determined in rat limbic system1994Journal of medicinal chemistry, Sep-30, Volume: 37, Issue:20
6,7,8,9-Tetrahydro-N,N-di-n-propyl-3H-benzindol-8-amines. Derivatives as potent and orally active serotonin 5-HT1A receptor agonists.
AID180539The compound was tested in vivo for DOPA accumulation in hemispheres (cortex) against reserpine-pretreated rats;I= inactive at the highest dose tested1995Journal of medicinal chemistry, Jun-09, Volume: 38, Issue:12
Structure-activity relationships in the 8-amino-6,7,8,9-tetrahydro-3H-benz[e]indole ring system. 1. Effects of substituents in the aromatic system on serotonin and dopamine receptor subtypes.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's4 (80.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (20.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (20.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other4 (80.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]